Commonly vaccinated routes, including subcutaneous, intradermal, or intramuscular injection, can induce protective systemic antibodies but exhibit weaker responses in the induction of substantial mucosal antibodies ( 1). For example, infection of influenza virus, severe acute respiratory syndrome coronavirus, Vibrio cholerae, and herpes simplex virus. Several infections start on mucosal surfaces. These results suggest that antigen-FLIPr fusion protein alone via intranasal administration can be applied to mucosal vaccine development. Furthermore, we employed immunodeficient AG129 mice as a Zika virus infection model and demonstrated that intranasal administration of recombinant Zika virus envelope protein domain III-FLIPr fusion protein induced protective immune responses against the Zika virus.
Importantly, activation of OVA-specific CD4 + and CD8 + T cells and induction of a broad-spectrum cytokine secretion profile were detected after intranasal administration of rOVA-FLIPr alone in immunocompetent C57BL/6 mice. Subsequently, OVA-specific IgG and IgA antibodies in the circulatory system and IgA antibodies in mucosal tissue were detected.
Our results demonstrate that intranasal administration of recombinant OVA-FLIPr fusion protein (rOVA-FLIPr) alone efficiently delivers OVA to DCs in nasal lymphoid tissue. We employed formyl peptide receptor-like 1 inhibitory protein (FLIPr), an FcγR antagonist secreted by Staphylococcus aureus, as a vector to target ovalbumin (OVA) to dendritic cells (DCs) via intranasal administration.
0 kommentar(er)
